Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Fineline Cube May 29, 2026
Company Deals Drug

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Fineline Cube May 29, 2026
Company Deals

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Fineline Cube May 29, 2026
Company Deals

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Fineline Cube May 29, 2026
Company Deals

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

Fineline Cube May 29, 2026
Policy / Regulatory

China’s NHSA Proposes First National Basic Medical Insurance Medical Service Items List to Standardize Reimbursement Framework

Fineline Cube May 29, 2026
Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Fineline Cube May 29, 2026
Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Fineline Cube May 29, 2026
Company Legal / IP

JD Healthcare’s H1 2022 Financial Report Shows Strong Growth in Revenue and Profits

Fineline Cube Aug 26, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), reported robust financial results...

Company

Everest Medicines CEO Resigns as Trodelvy Sale Completed

Fineline Cube Aug 26, 2022

China-based biotech Everest Medicines (HKG: 1952) announced the resignation of CEO Dr. Kerry Blanchard, effective...

Company Deals

Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech

Fineline Cube Aug 26, 2022

Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B...

Company Deals

Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform

Fineline Cube Aug 26, 2022

Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in...

Company Deals

Health Plus Receives Strategic Investment from Meinian Onehealth to Drive Healthcare Innovation

Fineline Cube Aug 26, 2022

Beijing-based Health Plus, a third-party digital managed healthcare service platform, has received strategic investment from...

Company Deals

Prismlab China Raises USD 29.1M in Series C for 3D Printing Expansion

Fineline Cube Aug 26, 2022

Shanghai-based 3D printing solution provider Prismlab China Ltd has raised RMB 200 million (USD 29.1...

Company Drug

Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company Drug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company

Novartis to Spin Off Sandoz, Focus on Innovative Drugs

Fineline Cube Aug 26, 2022

Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers

Fineline Cube Aug 26, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...

Company

CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...

Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...

Company

Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales

Fineline Cube Aug 25, 2022

China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...

Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Posts pagination

1 … 640 641 642 … 674

Recent updates

  • Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease
  • BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China
  • Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers
  • AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome
  • Shionogi’s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Company Drug

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

Company Drug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.